PCVX Price Prediction Next Week
Analysis and Insights
Fundamental Analysis:
Vaxcyte (PCVX) has a Strong Buy consensus among analysts, with a price target consensus of $147.17, suggesting significant upside potential. Recent analyst ratings, including a Buy rating from Mizuho Securities with a $149.43 target, further reinforce positive sentiment.
Technical Analysis:
The stock is currently trading at $70.27, with key Fibonacci levels indicating support at $67.25 and resistance at $81.20. The RSI_14 of 33.42 suggests the stock is oversold, potentially indicating a near-term bounce. However, the MACD remains bearish, with the MACD line (-3.82) below the signal line (-0.72).
News Sentiment and Insider Activity:
Recent news highlights Vaxcyte's strong position and future growth prospects, with analysts emphasizing its promising pipeline and strategic engagements. However, insider selling activity, including the sale of 2,085 shares by the COO, raises caution.
Price Prediction and Recommendation:
Given the oversold condition and potential support from Fibonacci levels, PCVX may experience a short-term bounce. The target price for the next trading week is $75.00. However, the overall bearish trend suggests caution, and this move may be part of a broader correction.
Recommendation: Buy with a target of $75.00, but be prepared for potential volatility.
PCVX Similar Chart Price Prediction
The price of PCVX is predicted to go up -10.39%, based on the high correlation periods with PBF. The similarity of these two price pattern on the periods is 98.11%.
PCVX
PBF
Down: -10.39%Similarity: 98.11%
PCVX Revenue Forecast
PCVX EPS Forecast
PCVX Analyst's Forecast
Chris Shibutani
Goldman Sachs
Strong Buy
2024-12-20
Price Target
$135
Upside
+56.02%
Goldman Sachs analyst Chris Shibutani initiated coverage of Vaxcyte with a Buy rating and $135 price target. The firm says clinical data for the company's lead programs provide a "foundation for viewing" its core longer-term fundamentals as "strongly positive." The recent relative underperformance of the shares, driven primarily by uncertainties deriving from broader macro and healthcare policy-related uncertainties, creates an "especially attractive entry point," the analyst tells investors in a research note. Goldman believes Vaxcyte's upcoming data in Q1 for VAX-24 in the infant and pediatric population "provides a potentially high impact near-term catalyst."
